Curium Receives Marketing Authorization In Switzerland For Piflufolastat (18F) – An Innovative PSMA PET Tracer Indicated In Patients With Prostate Cancer
Swissmedic grants marketing authorization for Piflufolastat (18F) in Switzerland e.imaging AG is marketing authoriz…